The role of dapagliflozin in non-compaction cardiomyopathy for refractory heart failure with reduced ejection fraction: 4th pillar for unstable disorder

Abstract

Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, has been shown in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study to significantly decrease mortality or hospitalisation in patients with heart failure with reduced ejection fraction (HFrEF). We describe a case of a patient with noncompaction cardiomyopathy (NCCM) who initially responded partially to guideline-directed medical therapy, which included an angiotensin receptor-neprilysin inhibitor (ARNI). However, the patient's symptoms returned, and the addition of dapagliflozin was able to provide a definitive improvement in his clinical-echocardiographic parameters. There is currently no data indicating that dapagliflozin is beneficial for patients with NCCM and HFrEF which progressive disorder.

Keywords

• Non-ischaemic cardiomyopathy
• Non-compaction
• Heart failure with reduced ejection fraction
• Angiotensin receptor-neprilysin inhibitor
• Sodium-glucose cotransporter-2 inhibitors